Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1465-993X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities ; volume:22 ; number:1 ; day:26 ; month:4 ; year:2021 ; pages:1-10 ; date:12.2021
Respiratory research ; 22, Heft 1 (26.4.2021), 1-10, 12.2021

Urheber
Glaspole, Ian
Bonella, Francesco
Bargagli, Elena
Glassberg, Marilyn K.
Caro, Fabian
Stansen, Wibke
Quaresma, Manuel
Orsatti, Leticia
Bendstrup, Elisabeth
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1186/s12931-021-01695-y
URN
urn:nbn:de:101:1-2021061719304014484555
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
14.08.2025, 10:54 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Glaspole, Ian
  • Bonella, Francesco
  • Bargagli, Elena
  • Glassberg, Marilyn K.
  • Caro, Fabian
  • Stansen, Wibke
  • Quaresma, Manuel
  • Orsatti, Leticia
  • Bendstrup, Elisabeth
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Patient Profile-Based Management with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Association between nintedanib adherence trajectory and healthcare use among idiopathic pulmonary fibrosis patients

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

Cost-Effectiveness Analysis of Nintedanib Versus Pirfenidone in Idiopathic Pulmonary Fibrosis in Belgium

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Pirfenidone vs. nintedanib in patients with idiopathic pulmonary fibrosis: a retrospective cohort study

Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study

Delineating excess comorbidities in idiopathic pulmonary fibrosis: an observational study

Verbundene Objekte